Fluorescein
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Fluorescein: From Diagnostic Angiography to Prinzmetal Angina
One-Sentence Summary
Fluorescein is a diagnostic dye used in ophthalmic and angiographic imaging, not a therapeutic drug. The TxGNN model predicts it may be effective for Prinzmetal angina, but this is a computational prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the license records (described as a diagnostic ophthalmic/angiographic dye) |
| Predicted New Indication | Prinzmetal angina |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 13 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Fluorescein is a diagnostic dye for ophthalmic and angiographic use. It works as a fluorescent marker, not as a treatment.
No mechanistic link to Prinzmetal angina was identified. Fluorescein has no known vasodilatory or anti-vasospastic activity, and Prinzmetal angina is driven by coronary artery vasospasm. The high score most likely reflects a knowledge-graph artifact rather than a real pharmacological relationship.
The same pattern appears in the other top-10 predictions (for example, coagulation-factor deficiencies and thrombophilia). Where any evidence was retrieved, it describes fluorescein as a diagnostic imaging tool, not a treatment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The five main authorizations are listed below. The records provide no approved-indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA 021980 | FLUORESCITE | Injection, solution | Alcon, Inc. |
| ANDA 215709 | Fluorescein | Injection | Nexus Pharmaceuticals LLC |
| NDA 022186 | AK-FLUOR | Injection | Long Grove Pharmaceuticals, LLC |
| N/A | Fluorescein Sodium Ophthalmic Strips | Strip | Vistamerica USA |
| N/A | GloStrips | Strip | Nomax Inc. |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials, no literature, and no plausible mechanism, so the evidence level is L5 (model prediction only). Fluorescein is a diagnostic dye with no known anti-vasospastic activity, and the high TxGNN score alone does not justify further investment.
To proceed, the following is needed:
- Mechanism of action data (MOA) and a plausible pharmacological link to coronary vasospasm
- Package insert warnings and contraindications, to allow a safety screen
- Preclinical or clinical evidence showing therapeutic activity, not diagnostic use
- Route compatibility assessment (current products are injectable or ophthalmic strips only)
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.